CẢI THIỆN KIỂM SOÁT ĐƯỜNG HUYẾT ở bệnh nhân trưởng thành đái tháo đường týp 2

Thông tin khoa học

Experts’ perspectives on the EMPA-REG OUTCOME

Experts’ perspectives on the EMPA-REG OUTCOME (Kramer CK and Zinman B) Eur Heart J 37(42):3201-3202, 2016.
In light of the results of the EMPA-REG OUTCOME study which demonstrate for the first time a robust beneficial impact of an antidiabetic medication on CV outcomes, the use of SGLT-2 inhibitors preferentially for the patient population with T2DM and established CV disease might represent a new treatment paradigm to prevent CV disease in that setting.

Three different specialty perspectives on EMPA-REG OUTCOME

Three different specialty perspectives on EMPA-REG OUTCOME
The endocrinologist's point of view (Perreault L. Am J Cardiol 120(S1):S48-S52, 2017.)
doi: 10.1016/j.amjcard.2017.05.010

Three different specialty perspectives on EMPA-REG OUTCOME The cardiologist's point of view (Pham SV, Chilton RJ. Am J Cardiol 120(S1):S53-S58, 2017)

Three different specialty perspectives on EMPA-REG OUTCOME
The cardiologist's point of view (Pham SV, Chilton RJ. Am J Cardiol 120(S1):S53-S58, 2017)
doi: 10.1016/j.amjcard.2017.05.011

Three different specialty perspectives on EMPA-REG OUTCOME The nephrologist's point of view (Wanner C. Am J Cardiol 120(S1):S59-S67, 2017.)

Three different specialty perspectives on EMPA-REG OUTCOME
The nephrologist's point of view (Wanner C. Am J Cardiol 120(S1):S59-S67, 2017.)
doi: 10.1016/j.amjcard.2017.05.012

Tubuloglomerular feedback and renal protection with empagliflozin

Tubuloglomerular feedback and renal protection with empagliflozin

Role of the cardiologist in diabetes management

Role of the cardiologist in diabetes management

Reductions in CV outcomes and CV mortality with empagliflozin in Asian patients

Reductions in CV outcomes and CV mortality with empagliflozin in Asian patients

PC-VN-100395
Production date: May 2019